Proficio Capital Partners LLC Acquires New Shares in Integer Holdings Co. (NYSE:ITGR)

Proficio Capital Partners LLC acquired a new stake in Integer Holdings Co. (NYSE:ITGR) in the fourth quarter, according to its most recent filing with the SEC. The fund acquired 16,565 shares of the medical equipment provider’s stock, valued at approximately $2,195,000.

A number of other hedge funds have also bought and sold shares of the business. Blue Trust Inc. grew its stake in Integer by 4.4% in the 4th quarter. Blue Trust Inc. now owns 1,689 shares of the medical equipment provider’s stock valued at $220,000 after buying an additional 71 shares in the last quarter. HighTower Advisors LLC grew its stake in Integer by 0.8% in the 3rd quarter. HighTower Advisors LLC now owns 12,041 shares of the medical equipment provider’s stock valued at $1,579,000 after buying an additional 90 shares in the last quarter. State of New Jersey Common Pension Fund D grew its stake in Integer by 0.9% in the 4th quarter. State of New Jersey Common Pension Fund D now owns 15,722 shares of the medical equipment provider’s stock valued at $2,083,000 after buying an additional 140 shares in the last quarter. Mather Group LLC. grew its stake in Integer by 304.3% in the 4th quarter. Mather Group LLC. now owns 190 shares of the medical equipment provider’s stock valued at $25,000 after buying an additional 143 shares in the last quarter. Finally, Exchange Traded Concepts LLC grew its position in shares of Integer by 2.6% during the 4th quarter. Exchange Traded Concepts LLC now owns 5,800 shares of the medical equipment provider’s stock valued at $769,000 after purchasing an additional 145 shares in the last quarter. 99.29% of the stock is currently owned by hedge funds and other institutional investors.

Integer Stock Up 3.9 %

Shares of NYSE:ITGR opened at $122.87 on Thursday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 2.09 and a current ratio of 2.95. The firm has a market capitalization of $4.13 billion, a PE ratio of 36.57, a price-to-earnings-growth ratio of 1.72 and a beta of 1.13. The firm has a fifty day moving average of $136.01 and a 200 day moving average of $132.95. Integer Holdings Co. has a 52-week low of $107.11 and a 52-week high of $146.36.

Integer (NYSE:ITGR) last posted its quarterly earnings results on Thursday, February 20th. The medical equipment provider reported $1.43 earnings per share for the quarter, missing the consensus estimate of $1.46 by ($0.03). The business had revenue of $449.50 million during the quarter, compared to the consensus estimate of $446.28 million. Integer had a return on equity of 11.65% and a net margin of 6.92%. As a group, research analysts anticipate that Integer Holdings Co. will post 6.01 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

ITGR has been the subject of a number of recent analyst reports. Benchmark boosted their price target on shares of Integer from $140.00 to $150.00 and gave the company a “buy” rating in a research report on Friday, February 21st. Wells Fargo & Company restated an “overweight” rating and set a $160.00 price target on shares of Integer in a research report on Tuesday, December 3rd. Oppenheimer lowered shares of Integer from an “outperform” rating to a “market perform” rating in a research report on Friday, February 21st. Citigroup boosted their price target on shares of Integer from $130.00 to $145.00 and gave the company a “neutral” rating in a research report on Wednesday, December 11th. Finally, Truist Financial boosted their price target on shares of Integer from $147.00 to $163.00 and gave the company a “buy” rating in a research report on Wednesday, December 11th. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $147.67.

Integer Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.